Alpha 2.0
Login Register
» Authors » Matthias M Heck

Matthias M Heck

Explore the profile of Matthias M Heck including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 46
Citations 1068
Followers 0
Related Specialties
Urology
Oncology
Nuclear Medicine
Top 10 Co-Authors
Jurgen E Gschwend
Matthias Eiber
Tobias Maurer
Margitta Retz
Isabel Rauscher
Mark Thalgott
Roman Nawroth
Thomas Horn
Robert Tauber
Markus Schwaiger
Published In
Eur Urol
J Nucl Med
Eur J Nucl Med Mol Imaging
Urol Oncol
Eur Urol Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Prognostic F-flotufolastat PET parameters for outcome assessment of Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer
Karimzadeh A, Hansen K, Hasa E, Haller B, Heck M, Tauber R, et al.
Eur J Nucl Med Mol Imaging . 2025 Jan; PMID: 39847077
Purpose: This retrospective analysis evaluates baseline F-flotufolastat positron emission tomography (PET) parameters as prognostic parameters for treatment response and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment...
2.
Prostate-specific Membrane Antigen-radioguided Surgery in an EMBARK-like Cohort of Patients with Oligorecurrent Hormone-sensitive Prostate Cancer: Delay in Systemic Treatment
Falkenbach F, Lischewski F, Knipper S, Koehler D, Karakiewicz P, Tian Z, et al.
Eur Urol Focus . 2025 Jan; PMID: 39843283
We analyzed data for a cohort of 111 patients with EMBARK-like biochemical recurrence (BCR) of prostate cancer (prostate-specific antigen [PSA] doubling time ≤9 mo, PSA ≥1 ng/ml) after radical prostatectomy...
3.
Matched-pair analysis of mCRPC patients receiving Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval
Karimzadeh A, Hecker C, Heck M, Tauber R, DAlessandria C, Weber W, et al.
EJNMMI Res . 2024 Oct; 14(1):94. PMID: 39402311
Background: The optimal regimen for Lu-labeled prostate-specific membrane antigen-targeted radioligand therapy, including treatment intervals, remains under study, with evidence suggesting shorter intervals could benefit patients with high disease volume and...
4.
Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery
Knipper S, Lischewski F, Koehler D, Eiber M, van Leeuwen F, de Barros H, et al.
Eur Urol Oncol . 2024 May; PMID: 38729805
Background: In a subset of patients with oligorecurrent prostate cancer (PCa), salvage surgery with prostate-specific membrane antigen (PSMA) radioguided surgery (PSMA-RGS) seems to be of value. Objective: To evaluate whether...
5.
EAU Biochemical Recurrence Risk Classification and PSA Kinetics Have No Value for Patient Selection in PSMA-Radioguided Surgery (PSMA-RGS) for Oligorecurrent Prostate Cancer
Falkenbach F, Ambrosini F, Tennstedt P, Eiber M, Heck M, Preisser F, et al.
Cancers (Basel) . 2023 Oct; 15(20). PMID: 37894375
Objective: To assess the influence of biochemical recurrence (BCR) risk groups and PSA kinetics on the outcomes of radioguided surgery against prostate-specific membrane antigen (PSMA-RGS). Currently, neither BCR risk group...
6.
Improved Quality of Life in Metastatic Castration-Resistant Prostate Cancer Patients Receiving Consecutive Cycles of Lu-PSMA I&T
Karimzadeh A, Soeiro P, Feuerecker B, Hecker C, Knorr K, Heck M, et al.
J Nucl Med . 2023 Sep; 64(11):1765-1771. PMID: 37678925
The aim of this retrospective analysis was to evaluate health-related quality of life (HRQoL) for patients with metastatic castration-resistant prostate cancer (mCRPC) receiving consecutive cycles of Lu-prostate-specific membrane antigen (PSMA)...
7.
Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support
Falkenbach F, Knipper S, Koehler D, Ambrosini F, Steuber T, Graefen M, et al.
World J Urol . 2023 Jul; 41(9):2343-2350. PMID: 37515651
Background And Objective: Metastasis-directed therapy is a feasible option for low PSA, recurrent locoregional metastatic prostate cancer. After initial salvage surgery, patients with good response might consider a repeat salvage...
8.
Development and external validation of a multivariable [Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer
Muehlematter U, Schweiger L, Ferraro D, Hermanns T, Maurer T, Heck M, et al.
Eur J Nucl Med Mol Imaging . 2023 Jun; 50(10):3137-3146. PMID: 37261472
Purpose: To develop and evaluate a lymph node invasion (LNI) prediction model for men staged with [Ga]Ga-PSMA-11 PET. Methods: A consecutive sample of intermediate to high-risk prostate cancer (PCa) patients...
9.
Prostate-specific Membrane Antigen-radioguided Surgery Facilitates Pelvic Lymph Node Dissection During Radical Prostatectomy for the Treatment of Locally Advanced Prostate Cancer with Regional Lymph Node Metastases
Lunger L, Steinhelfer L, Korn P, Eiber M, Maurer T, Buchler J, et al.
Eur Urol Oncol . 2023 Jan; 6(1):95-98. PMID: 36604297
Lymph node metastases (LNMs) are common in intermediate- to high-risk prostate cancer (PC) and may be missed during extended pelvic lymph node dissection (ePLND). Here we report on the use...
10.
Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery
Knipper S, Mehdi Irai M, Simon R, Koehler D, Rauscher I, Eiber M, et al.
Eur Urol . 2022 Jun; 83(1):62-69. PMID: 35718637
Background: In a subset of patients with recurrent oligometastatic prostate cancer (PCa) salvage surgery with prostate-specific membrane antigen (PSMA)-targeted radioguidance (PSMA-RGS) might be of value. Objective: To evaluate the oncological...